BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8443375)

  • 1. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
    Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
    J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
    Girouard C; Dufresne J; Imrie K; Stewart AK; Brandwein J; Prince HM; Pantolony D; Keating A; Crump M
    Ann Oncol; 1997 Jul; 8(7):675-80. PubMed ID: 9296221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
    Chopra R; Linch DC; McMillan AK; Blair S; Patterson KG; Moir D; Richards JD; Cervi P; Kinsey S; Goldstone AH
    Br J Haematol; 1992 Jun; 81(2):197-202. PubMed ID: 1643017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
    Linch DC; Winfield D; Goldstone AH; Moir D; Hancock B; McMillan A; Chopra R; Milligan D; Hudson GV
    Lancet; 1993 Apr; 341(8852):1051-4. PubMed ID: 8096958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
    J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Schmitz N; Pfistner B; Sextro M; Sieber M; Carella AM; Haenel M; Boissevain F; Zschaber R; Müller P; Kirchner H; Lohri A; Decker S; Koch B; Hasenclever D; Goldstone AH; Diehl V; ;
    Lancet; 2002 Jun; 359(9323):2065-71. PubMed ID: 12086759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
    Seymour LK; Dansey RD; Bezwoda WR
    Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
    Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
    Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
    Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L
    Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
    Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
    Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.